27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our objectives were to investigate the utility of the Hachinski Ischemic Score (HIS) in differentiating patients with pathologically verified Alzheimer's disease (AD), multi-infarct dementia (MID), and "mixed" (AD plus cerebrovascular disease) dementia, and to identify the specific items of the HIS that best discriminate those dementia subtypes. 4 key findings →
Design: meta-analysis Participants: 312 Evidence: high
Full summary, score breakdown and related studies → Original source
EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. 5 key findings →
Participants: 309 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
No difference was seen in Clinical Global Impression scores between patients receiving placebo and those receiving linopirdine (n = 189). 4 key findings →
Participants: 382 Evidence: high
Full summary, score breakdown and related studies → Original source
Furthermore, the dramatic and favorable effects on disturbing behaviors in AD suggest a novel approach for treatment of noncognitive symptoms. 1 key finding →
Participants: 343 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6); whereas, the ORs were decreased for people with genotypes epsilon2/epsilon2 (OR=0.6, 95% CI=0.2-2.0) and epsilon2/epsilon3 (OR=0.6, 95% CI=0.5-0.8). 2 key findings →
Participants: 5,930 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The APOE epsilon4 allele is a genetic risk factor for dementia with stroke, including VaD and AD with CVD. 5 key findings →
Design: case-control study Participants: 187 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We estimated the remaining lifetime risks of developing Alzheimer's disease (AD) and dementia from all causes, based on data from longitudinal population studies. 5 key findings →
Design: longitudinal study Participants: 198 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The prediction algorithms are a first but promising step toward providing specific prognoses to patients, families, and practitioners. 1 key finding →
Design: cohort study Participants: 236 Evidence: moderate
Full summary, score breakdown and related studies → Original source
If these results can be generalised then virtually all mental disorders have an increased risk of suicide excepting mental retardation and dementia. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
CIND is commonly associated with functional disability and a need for institutional care. 2 key findings →
Participants: 1,106 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is unclear whether persons with diabetes are at increased risk for dementia, including Alzheimer's disease. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These findings suggest that cerebrovascular disease may play an important role in determining the presence and severity of the clinical symptoms of AD. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
All indicators of atherosclerosis were associated with dementia (odds ratios ranging from 1.3 to 1.9) and its major subtypes Alzheimer's disease (odds ratios 1.3-1.8) and vascular dementia (odds ratios 1.9-3.2). 4 key findings →
Participants: 284 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Tacrine stabilizes or improves specific behavioral deficits and symptoms in AD. 1 key finding →
Participants: 181 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The current study is a controlled clinical investigation of two nonpharmacological treatments of depression in patients with Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Full summary, score breakdown and related studies → Original source Free full text
To assess the relationship between dementia, neuronal loss, and neuropathological findings in Alzheimer's disease (AD), we counted the number of neurons, senile plaques, and neurofibrillary tangles in a high-order association cortex. 1 key finding →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia and subtypes Alzheimer's disease and vascular dementia may be related to atrial fibrillation even if no clinical stokes have occurred. 2 key findings →
Design: cross-sectional Participants: 6,584 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clinical diagnosis of probable Alzheimer's disease is possible, using [18F]fluorodeoxyglucose positron emission tomography. 3 key findings →
Participants: 66 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
(1) The incidence of dementia increases with age, even in the oldest age groups; (2) women have a higher risk of developing dementia than men, especially at very old ages; (3) this pattern is mainly due to the age and gender distribution of Alzheimer's disease, rather than vascular dementia. 2 key findings →
Participants: 1,473 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parkinson's disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). 4 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI. 5 key findings →
Participants: 309 Evidence: high
Full summary, score breakdown and related studies → Original source
Risk of VaD was associated with history of arterial hypertension (OR, 2.08; 95% confidence interval, 1.29 to 3.35). 5 key findings →
Design: case-control study Participants: 129 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →